(
out of
745
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital North
2K, Gynecology and Mammography
1950 Circle of Hope
Salt Lake City
,
UT
84112
Specialties
Board Certification
|
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
|
Patient Rating
Patients consistently describe Dr. Vaklavas as highly knowledgeable and thorough, explaining diagnoses and treatment options clearly and often using diagrams or written notes. Reviewers highlight his strong communication and bedside manner—he listens, answers questions patiently, involves patients in decisions, and treats them with respect and empathy. Many also note his responsiveness and attentiveness to follow-up and individualized care, leaving patients feeling informed, supported, and confident in their treatment plan.
Generated via Patient Reviews
4.9
/5
( out of
745 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor |
|---|---|
| Academic Divisions |
Oncology
|
| Board Certification |
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
|
Selected Publications
Journal Article
- Coletta AM, Playdon MC, Baron KG, Wei M, Kelley K, Vaklavas C, Beck A, Buys SS, Chipman J, Ulrich CM, Walker D, White S, Oza S, Zingg RW, Hansen PA (2021). The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors. PLoS One, 16(10:e0258135).
- Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM, I-SPY2 Trial Team (2021). Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clin Cancer Res, 27(19), 5299-5306.
- Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES (2021). An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. . Breast Cancer Res, 23(1:30).
- Chae YK, Hong F, Vaklavas C, Cheng HC, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, ODwyer PJ, Chen AP, Flaherty KT (2020). A Phase II Study of AZD4547 in Patients with Tumors harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Sub-protocol W. J Clin Oncol, 38(21), 2407-2417.
- Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, ODwyer PJ, Chen AP, Flaherty KT (2020). Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol, 38(21), 2407-2417.
- Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A on behalf of the Translational Breast Cancer Research Consortium (2020). TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole with or without bevacizumab in post-menopausal women with newly diagnosed stage II/III hormone receptor positive and HER2 negative breast cancer. Breast Cancer Res, 22(1:22).
- Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A, Translational Breast Cancer Research Consortium TBCRC (2020). TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res, 22(1), 22.
- Vaklavas C, Blume SW, Grizzle WE (2020). Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer. . Transl Oncol, 13(2), 452-470.
- Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V (2019). TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol, 37(9), 714-722.
- Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW (2018). Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition. Oncol Rep, 39(6), 2482-2498.
- Vaklavas C, Blume SW, Grizzle WE (2017). Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. Front Oncol, 7, 158.
- Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2016). Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget, 8(9), 16052-16074.
- Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW (2016). IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells. Tumour Biol, 37(10), 13247-13264.
- Rugo HS, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med, 375(1), 23-34.
- Park JW, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med, 375(1), 11-22.
- Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE (2016). Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res, 4(5), 390-9.
- Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D (2015). Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat? Semin Oncol, 42(4), e67-79.
- Turner NC, et al, PALOMA3 Study Group (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373(3), 209-19.
- Paoletti C, Li Y, Muiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, Translational Breast Cancer Research Consortium TBCRC (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res, 21(12), 2771-9.
- Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium TBCRC (2015). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res, 21(12), 2722-9.
- Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW (2015). Small molecule inhibitors of IRES-mediated translation. Cancer Biol Ther, 16(10), 1471-85.
- Vaklavas C, Forero A (2014). Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs, 28(3), 253-63.
- Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R (2014). Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology, 60(127), 1611-23.
- Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A (2013). Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm, 28(5), 370-9.
- Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ (2013). A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol, 40(2), 135-44.
- Vaklavas C, Forero-Torres A (2013). Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol, 3(4), 209-25.
- Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2011). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8.
- Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE (2012). By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes. J Natl Compr Canc Netw, 10(1), 7-13.
- Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM (2011). A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics. Clin Lymphoma Myeloma Leuk, 11(6), 521-4.
- Vaklavas C, Forero-Torres A (2011). How do I treat "triple-negative" disease. Curr Treat Options Oncol, 12(4), 369-88.
- Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011). Common cardiovascular medications in cancer therapeutics. Pharmacol Ther, 130(2), 177-90.
- Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R (2010). Phase 1 clinical trials in 83 patients with pancreatic cancer: The M.D. Anderson Cancer Center experience. Cancer, 117(1), 77-85.
- Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM (2010). Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J, 7, 256.
- Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010). Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf, 33(3), 171-87.
- Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ (2010). Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res, 16(4), 1149-58.
- Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010). Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist, 15(2), 130-41.
- Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ (2009). Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol, 31(11), 803-11.
- Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R (2009). Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab, 94(11), 4423-32.
- Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2008). Molecular basis of statin-associated myopathy. Atherosclerosis, 202(1), 18-28.
- Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A (2006). 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res, 31(5), 691-4.
- Christakis C, Vaklavas C, Kontos N, Chatzidimitriou C, Tzelepi K, Karanikas M, Christakis E (2005). Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts. Tech Coloproctol, 8 Suppl 1, s85-8.
Book Chapter
- Vaklavas C, LoBuglio AF, Saleh M, Yelin M, Forero A (2013). CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE). In Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 211-20). Springer.
- Forero A, Vaklavas C, LoBuglio AF (2013). Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies. In Antibody- Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 161-75). Springer.
Editorial
- Welm BE, Vaklavas C, Welm AL (2021). Toward improved models of human cancer. 5(1).
- Vaklavas C, Chatzizisis YS (2010). The changing perspective of cardiology in cancer care. Expert Rev Cardiovasc Ther, 9(1), 1-3.
Letter
- Chatzizisis YS, Vaklavas C, Giannoglou GD (2007). Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy? [Letter to the editor]. Am J Cardiol, 101(7), 1071.
Other
- Welm BE, Vaklavas C, Welm AL (2021). Erratum: "Toward improved models of human cancer" [APL Bioeng. 5, 010901 (2021)]. APL Bioeng (5(2), p. 029901). United States.
Very good [TRANSLATED]
He's a great Doc that's doing what he can within the constraints of what the University supplies.
I am very fortunate to find myself in his care at a critical time.
Wonderful doctor and man. I feel totally comfortable being in his care Hrs patient, kind, and very thorough.
Wonderful doctor. This is the third location I have gone to for my cancer and he was the only one who listened to what I wanted and formulated a plan around that.
Dr. Vaclavas is the best doctor I have privilege to receive care from. He is very knowledgeable, patient, caring. He pays full attention to everything l have to say and answer all of my questions in every detail. I am very lucky to have him as my oncologist.
He was kind and answered my questions
Dr Vaklavas is the best. I would choose him to care for any of my family and friends.
Dr Vaklavas is super smart and I feel so lucky to be in his care. He always listens to carefully and takes time to help me understand my situation and available options. I love how he writes things down for me and explains things thoroughly and helps me understand the research and data supporting each option and recommendation. He is thoughtful, thorough, kind, respectful and professional, and I also appreciate his fun sense of humor.
He is excellent, shows he cares
If I had one message to leave with people it would be 'Please go straight to Huntsman Cancer Institute. Dr Vaklavas reacted immediately and has followed up without a If I could leave one message to people it would be 'go straight to Huntsman Cancer Institute if they have any concerns. Dr Vaklavas reacted immediately and has not hesitated to quickly follow up. This was not happening before I decided to go there.
Dr. Vaklavas and University of Utah Farmington Oncology are superior to any other I've encountered in 25 years of fighting cancer.
He is the best. He was prepared for the visit with a thorough review of my history. He is very knowledgeable, and has great people skills.
Dr Vaklavas is very up to date on all my cancer problems and working very hard on my plan of care. He explains my treatments, results and includes my husband who accompanies me. He has a great team also.
Dr. Vaklavas is a 5 out 5 stars. I highly recommend him!!
Definitely book an appointment with Dr. Vaklavas. He is the third oncologist I have seen and is the only one that actually listened to me and had options for me. He didn't just rubber stamp my care plan the same as ever other patient. I left his appointment feeling so optimistic and with a breath of fresh air.
Dr. Vaklavas is the best of the best. If you're a woman and need a breast Oncologist, you need Dr. Vaklavas. He'll become your best friend by caring about every single little detail about your life and what's going on with you. He treats everything that pops up even though he's not a family physician, you may think so though, as he treats your breast cancer he treats the total you. He truly cares.
Very good explaining everything about my health care!
I feel truly grateful to have Christos Vaklava,MD.as my breast cancer doctor. I trust him explicitly with all decisions concerning my care. I have thrived with his treatments and the care I have received at Huntsman. If you are dealing with cancer in your life, I highly recommend you seek out the doctors at Huntsman.
Very aware of all of the new changes and progress in my diagnosis.
10/10 would recommend. Dr. Vaklavas is extremely caring and kind. He does a very good job of explaining the treatment processes, side effects, and potential side effects. He included me in all of the decisions about my care and explained the options that were available to me.
If you have to go through breast cancer, this is the doctor you want to treat you. He has been a literal lifesaver for me.
Very thorough and caring about his patients.
He's very knowledgeable and researches things I bring about NIH studies conducted. My cancer is bad, really bad. Stage 4 TNBC and it's mutated limiting treatment options. He's spent time research more out of the box ideas to avoid treatment with an 80% failure rate due to it not tolerable. He's a very good doctor. And his accent is pretty cool.
Great care and concern shown. Clear communication as to medical conditions and what comes next.
Dr Vaklavas was completely up to date on my history, condition and plan of care. Careful exam with suggestions about quality of life. Answered my husband's question about continued future care. I am very happy with my team.
Dr. Vaklavas is the best of the best!
Dr Vaklavas attention to detail, responsiveness, and advocacy for the best treatment options has given me total confidence that I'm receiving the best care. I'm beyond grateful for his support and would recommend Dr. Vaklavas without hesitation to anyone facing a cancer diagnosis.
Can't say enough good things about Dr. Vaklavas¿
After having my first visit with Dr. Vaklavas, I felt heard, he was kind, compassionate and I felt he truly wants what's best for me and will do all he can to do his best.
The professionalism and care you get from Dr. Vaklavas is out of this world.
He is ever sweet and funny
Great Dr. Very knowledgeable and kind.
Great doctor
Nice personality, but I didn't get answers to all my questions. Despite research proof of switching meds for better results, no change was made, even though I wanted it and it was very possible I had built up a resistance to what I'm on. I always leave feeling frustrated.
Dr vaklavos is amazing. He takes the time to remember the small details of you and for me my spouse. He is so awesome. We never felt rushed. My spouse and myself both feel he is top notch. I adore him. God bless he and his family.
I've had only good experiences with dr vaklavas
Excellent doctor with great compassion and care. No one wants to be seeing a doctor for cancer, but he is great at putting patients at ease, answering questions and explaining things. I especially appreciated that he stated that he wanted to 'partner with me' on my care and is willing to work with me for a treatment that I'm comfortable with even if it is a variation from what he'd typically recommend. I'm so grateful for Dr. Vaklavas!
Doctor Vaklavas is an excellent and caring physician. I am grateful to have him care for me.
I really like Dr. Vaklavas, he did run about 1/2 hour late for our appointment.
He was very focused on me and never had to refer to the computer about what my issue was, he knew. He figured out why I was having pain within minutes after I had been dismissed by other doctors. Would highly recommend. He makes you feel heard and that your comfort and well being is important.
Makes me laugh as always. Great doctor and his humor puts me wt ease. Feel very cared for with kindness.
He is capable, listens to my concerns and is kind and caring. I have confidence in him.
Excellent. Care is always top notch mixed in with excellent bedside manner and humor. Come out of there much lighter feeling knowing I'm get the best care and respect possible.
My visits with Dr. Vaklavas are always great, I always come out feeling good with my progress.
Dr. Vaklavas is wonderful! We are so thankful for his kindness and excellent care.
I would highly recommend my doctor.
He's an excellent physician. Always up to date on the latest advancements. His bedside manner is benchmark!
I think Dr. Vaklavas is one of the finest clinicians I have ever met and I worked in healthcare. During an annual visit, he reviewed my history before entering the room, he took time to listen to my concerns and do a thorough physical exam. Our conversation was full of helpful information. I am grateful to Dr. Vaklavas for the excellent care he has provided over the past few years.
Dr. Vaklavas is a very caring, attentive oncologist. He takes the time to listen to his patients and explains everything is a manner the patient can understand.
Puts tomorrow along with facts to make you feel less nervous where you listen more carefully to facts. Very pleased.
Very good explaining everything!
As I've said before, he is very nice and respectful, but not knowledgable of integrative treatments, new treatments, and doesn't seem to care to learn about them. I go in with all kinds of information, but he never seems very interested. Everyone at the Huntsman wants to push standard of care, when a lot of other alternatives are out there.
He has an awesome bed side manner. He explains things in a way that someone that is not in the medical field can thoroughly understand. This is a very stressful time in our life, talking and being treated by Dr. Vaklavas helps us maintain hope.
Very knowledgeable and tell the facts but in a kind and understandable way.
Very kind and talented. Great!
Dr. Vaklavas and his team are amazing !!!
He is an awesome person and a great doctor
My visit with Dr. Vaklavas are always positive, professional and informative. He is very knowledgeable and answers my questions in a way that is easy to understand.
Dr. Vaklavas is a great doctor with the knowledge of what treatment is best for my particular health problem. He makes an effort to help me understand my condition and I am grateful that he is my doctor.
I appreciated Dr. Vaklavas's concern about me and the best route to take for my treatment.
Dr. Vaklavas explains everything carefully and draws diagrams, timeliness whatever we need to understand treatment and results and the way the cancer cells are responding. He is very respectful of our questions and takes time to answer them all. He is personable and kind. He is very respectful and concerned for modesty. We are very grateful for his expertise as well as his thoughtfulness.
I can't say enough about this Doctor. He is very polite, proffesional, empathetic, knowledgeable, upbeat...he makes sure you understand about your cancer, the amount of it, what his treatment will be and why you need the treatment. He makes sure I understand and if I have any more questions. Gives me the number in case I need him before my next appointment and is upbeat so I can be also. 100% recommend this Doctor as any persons Oncologist.
Personable and respectful. Wish he had more knowledge of alternate treatments (non-invasive) and the care to suggest them.
Dr. V is the BEST!
Very knowledgeable and explains your health and procedures to patients. Friendly and on time!
Dr. Vaklavas is a very caring and knowledgeable person. He is very open to questions and explains all information and treatments so a new patient to cancer can understand.
Visit wasn't rushed, went over a lot of information & answered many questions.
Dr. Vaklavas showed respect and kindness to me. His caring attitude helped me to relax and focus on the information he clearly provided. I'm grateful for his medical knowledge and expert care as a physician.
He's a great Dr. and listens to me and answers my questions' He never treats as if my questions are dumb
Dr. Vaklavas is very knowledgeable and kind. He listens well and really cares about cancer patients. Nurse Anna is super sharp and very involved in patient care. She and Dr. V are a great team!
Unlike other doctors, I truly look forward to seeing him. He seems totally invested in giving you the best care available. Ask him a question and he will put on a seminar to answer it. Express a concern, and he will address it. He listens. He cares.
Very kind, attentive, gives good advice, is a good professional. [TRANSLATED]
Dr. Vaklavas is one of the most compassionate and caring doctors I have met at Huntsman. His knowledge of my condition and explanation to me is by far one of the reasons I would never go elsewhere. I'm blessed to have him as my oncologist.
Dr. Vaklavas is genuinely invested in each patient. Considering that care for one may be different for another. He listens and makes decisions and changes treatment as needed. He is brilliant in the Breast Cancer field and even notates scientific studies that relate to information we discussed at my appointments so I can refer back to it. Thanks to Dr. Vaklavas and his team! They have never failed me and I appreciate them greatly.
Dr. Vaklavas and his team teach and listen well. They respond quickly to my questions and concerns on my chart.
He is very thorough during our visit, making sure everything is going as planned.